In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Eisai gets epigenetic enzyme development rights from Epizyme; Epizyme takes back most rights

Executive Summary

Japanese health care company Eisai Co. Ltd. has licensed worldwide rights to discover, develop, and sell new cancer drugs targeting Epizyme Inc.’s (personalized therapeutics) EZH2 epigenetic enzyme.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register